Journal of Education and Health Promotion · Oct 2026
Cost-effectiveness and cost-utility of multiparametric magnetic resonance imaging with biopsy versus targeted or systematic transrectal ultrasound-guided biopsy for PCa screening and diagnosis: A systematic review
By Parnian E, Daroudi R, Hadian M et al.
According to GLOBOCAN, about 1.41 million new prostate cancer (PCa) cases were registered in the year 2020 globally. PCa is a costly disease, with diagnostic interventions being a major contributor to the rising costs of the disease. This review compared the cost-effectiveness and cost-utility studies of multiparametric magnetic resonance imaging (mpMRI)-guided biopsy (MRGB) with systematic transrectal ultrasonography (TRUS)-guided biopsy for screening and diagnosing PCa. PubMed, Web of Science, Embase, WorldCat, NHS Economic, Scopus, OATD, Tuffs registry, and the reference lists of the included studies were searched with no date restrictions through October 2024. The reporting quality of included studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist. This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. The lowest and highest numerical values of outcome measures were 6.50 and 46,717,192 QALY, respectively. The lowest and highest numerical value of the cost were 251.326$ and 513877.91$, respectively. All studies found that mpMRI, bpMRI, and MRGB were cost-effective in men with a negative biopsy. This study showed that MRI-guided biopsy before TRUS was superior to TRUS-guided biopsy alone due to convenience, higher QALY, and lower cost. bpMRI and mpMRI were more cost-effective than TRUS-guided biopsy. This review suggested that biopsy strategies combined with magnetic resonance imaging were superior to biopsy methods alone and should be considered a good option for screening and diagnosing PCa among men with PCa and suspected of having PCa.